APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels

Clinical Chemistry and Laboratory Medicine

Volumn 46, Issue 6, 2008, Pages 773-777

  Hubacek, Jaroslav A ^a,b   Wang, Wu Wei ^c   Škodová, Zdena ^a   Adámková, Věra ^a   Vráblík, Michal ^d   Hořínek, Aleš ^d   Štulc, Tomáš ^d   Češka, Richard ^d   Talmud, Philippa J ^c  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b Ctr for Exp Cardiovasc Research   (Czech Republic)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Apolipoprotein A5; Mutation; Triglycerides

Indexed keywords

APOLIPOPROTEIN A5; DNA; TRIACYLGLYCEROL;

ADULT; AGED; APOA5 GENE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DNA SEQUENCE; FEMALE; GENE; GENE MUTATION; HETEROZYGOTE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; APOLIPOPROTEINS A; CHOLESTEROL; CZECHOSLOVAKIA; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; MUTATION; TRIGLYCERIDES;

MUS;

EID: 44949195703     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2008.160     Document Type: Article

References (20)

1. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox JC, Fruchart JC, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001;294:169-73.
2. O'Brien PJ, Alborn WE, Sloan JH, Ulmer M, Boodhoo A, Knoerman MD, et al. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem 2005;51:351-9.
3. Baroukh N, Bauge E, Akiyama J, Chang J, Afzal V, Fruchart JC, et al. Analysis of apolipoprotein A5, C3, and plasma triglyceride concentrations in genetically engineered mice. Arterioscler Thromb Vasc Biol 2004;24:1297-302.
4. Hubacek JA. Apolipoprotein A5 and triglyceridemia. Focus on the effects of the common variants. Clin Chem Lab Med 2005;43:897-902.
5. Pennacchio LA, Olivier M, Hubacek JA, Krauss RM, Rubin EM, Cohen JC. Two independent apolipoprotein AV haplotypes influence human plasma triglyceride levels. Hum Mol Genet 2002;11:3031-8.
6. Talmud PJ, Hawe E, Martin S, Olivier M, Miller GJ, Rubin EM, et al. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet 2002;11:3039-46.
7. Lai CQ, Tai ES, Tan CE, Cutter J, Chew SK, Zhu YP, et al. The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore. J Lipid Res 2003;44:2365-73.
8. Hubáček JA, Škodová Z, Adámková V, Lánská V, Poledne R. The influence of APOAV polymorphisms (T-1131>C and S19>W) on plasma triglyceride levels and risk of myocardial infarction. Clin Genet 2004;65:126-30.
9. Szalai C, Keszei M, Duba J, Proházska Z, Kozma GT, Csásár A, et al. Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease. Atherosclerosis 2004;173:109-14.
10. Schaap FG, Rensen PC, Voshol PJ, Vrins C, van der Vliet HN, Chamuleau RA, et al. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem 2004;279:27941-7.
11. Fruchart-Najib J, Bauge E, Niculescu LS, Pham T, Tho mas B, Rommens C, et al. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun 2004;319:397-404.
12. Priore Oliva CP, Pisciotta L, Li Volti G, Sambataro MP, Cantafora A, Bellocchio A, et al. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2005;25:411-7.
13. Marcais C, Verges B, Charriere S, Pruneta V, Merlin M, Billon S, et al. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest 2005;115:2862-9.
14. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for DNA extraction from human nucleated cells. Nucleic Acid Res 1988;16:1215.
15. Day IN, Humphries SE. Electrophoresis for genotyping: microtiter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose. Anal Biochem 1994;222:389-95.
16. Priore Oliva CP, Tarugi P, Calandra S, Pisciotta L, Bellocchio A, Bertolini S, et al. A novel sequence variant in APOA5 gene found in patients with severe hypertriglyceridemia. Atherosclerosis 2006;188:215-7.
17. Schaefer JR, Sattler AM, Hackler B, Kurt B, Hackler R, Maisch B, et al. Hyperlipidemia in patients with apolipoprotein E 2/2 phenotype: apolipoprotein A5 S19W mutation as a cofactor. Clin Chem 2004;50:2214.
18. Hubacek JA, Horinek A, Skodova Z, Adamkova V, Ceska R, Zlatohlavek L, et al. Hypertriglyceridemia: interaction between APOE and APOAV variants. Clin Chem 2005;51:1311-3.
19. Evans D, Seedorf U, Beil FU. Polymorphisms in the apolipoprotein A5 (APOA5) gene and type III hyperlipidemia. Clin Genet 2005;68:369-72.
20. Talmud PJ. Rare APOA5 mutations - clinical consequences, metabolic and functional effects. Atherosclerosis 2007;194:287-92.